Last updated: February 15, 2026
Overview of NDC 00173-0644
NDC 00173-0644 refers to Nivolumab (marketed as Opdivo), a PD-1 immune checkpoint inhibitor. Approved by the FDA in 2014 for multiple cancer indications, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, nivolumab has become a key player in oncology therapeutics.
Market Size and Demand Drivers
Global Oncology Drugs Market: Valued at USD 220 billion in 2022, with an expected compound annual growth rate (CAGR) of 8.4% from 2023 to 2030 (source [1]).
Nivolumab's Market Share: As of 2022, nivolumab led the PD-1/PD-L1 class with approximately $7.5 billion in global sales. This accounts for roughly 15-20% of the broader immuno-oncology market, which surpassed $35 billion globally (source [2]).
Key Drivers:
- Approved indications expand annually, including head and neck cancers, hepatocellular carcinoma, and gastric cancers.
- Multiple combination therapies with nivolumab increase delineation into previously untapped markets.
- Expanding indications in emerging markets open further growth avenues.
Competitive Landscape
Top Competitors:
- Pembrolizumab (Keytruda): Dominates with over $20 billion in sales (2022).
- Atezolizumab and Durvalumab: Smaller but growing shares.
- Biosimilars: Currently limited for nivolumab, but expected to evolve over next 5 years.
Market Penetration:
- Nivolumab has high adoption rates in developed regions; penetration in emerging markets remains limited due to pricing and reimbursement issues.
Price Trends and Projections
Current Pricing:
- Wholesale acquisition cost (WAC): Approx. $6,600 per 40 mg dose (source [3]).
- Per-treatment course costs in the U.S.: Ranges from $60,000 to $150,000, depending on indication and dosing scheme.
Market Price Dynamics:
- The price of nivolumab remains relatively stable but faces downward pressure from biosimilar entry and negotiations.
- U.S. federal and commercial payors seek discounts; average net prices are estimated 20-30% lower than WAC.
Forecasted Price Trends (2023–2030):
| Year |
Estimated Average WAC per Dose |
Notes |
| 2023 |
$6,600 |
Stable, with minor regional variations |
| 2025 |
$6,300 |
Slight discounts from increased competition |
| 2027 |
$5,900 |
Entry of biosimilars, but limited impact in US |
| 2030 |
$5,600 |
Continued discounts, expansion into emerging markets |
Impacts on Price:
- Biosimilar development could lower prices by 20% in developed markets.
- Patent expiry for some formulations scheduled around 2029-2030, influencing price reductions.
- Reimbursement negotiations could accelerate discounts.
Implications for Stakeholders
- Pharmaceutical Companies: Investment in biosimilar development and indication expansion necessary to sustain profitability.
- Investors: Expected revenue potential remains high, but margin pressures are likely.
- Healthcare Systems: Cost containment pressures motivate negotiations and formulary adjustments.
Regulatory and Policy Outlook
- Ongoing patent litigations potentially delaying biosimilar entry in key markets.
- Reimbursement policies in the U.S. and Europe increasingly favor lower-cost biologics.
- Price negotiation models, such as value-based agreements, gaining traction, influencing future pricing strategies.
Summary
Nivolumab (NDC 00173-0644) maintains a dominant role in immuno-oncology with sustained high sales, driven by expanding indications and combination therapies. Price projections indicate stability in the short term, with modest declines forecasted over the next decade primarily due to biosimilars and patent expiries. Market dynamics are sensitive to regulatory, competitive, and reimbursement factors.
Key Takeaways
- Nivolumab’s global sales exceeded $7.5 billion in 2022.
- Wholesale prices are approximately $6,600 per dose; net prices are lower.
- Market penetration is high in developed regions; emerging markets pose growth opportunities.
- Biosimilar competition may reduce prices by approximately 20% by 2030.
- Patent expiries around 2029-2030 will influence pricing strategies.
5 FAQs
Q1: What indicates the current market potential for nivolumab?
A1: The expanding indications, high adoption rate in key markets, and ongoing clinical trials suggest continued strong demand through 2030, especially in combination regimens.
Q2: How might biosimilars influence nivolumab pricing?
A2: Biosimilar entry is expected to reduce prices by 20-30% in developed markets, primarily through increased competition and negotiation strategies.
Q3: Are there regional differences in pricing?
A3: Yes. U.S. prices average around $6,600 per 40 mg dose, while prices in Europe and Asia vary based on negotiations, reimbursement policies, and regulatory frameworks.
Q4: What are the key risks to the price projections?
A4: Patent expiries, biosimilar launches, regulatory changes, and shifts in reimbursement policies represent primary risks.
Q5: How can market entrants capitalize on future trends?
A5: Focusing on biosimilar development, optimizing indication expansion, and strategic pricing adjustments in emerging markets are key opportunities.
References
- Grand View Research. Oncology Drugs Market Size & Trends. 2022.
- IQVIA. The Impact of Immuno-Oncology in Global Markets. 2022.
- Drug Pricing Data. U.S. Wholesale Acquisition Cost (WAC) for Nivolumab. 2023.
